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Abstract: Pancreatic ductal adenocarcinoma is a stroma-rich and highly challenging cancer to 
treat. Over recent years, it has become increasingly evident that the complex network of soluble 
cytokines, growth factors, proteases, and components of the extracellular matrix collaboratively 
interact within the tumor microenvironment, sustaining and driving cancer cell proliferation, 
invasion, and early metastasis. More recently, the tumor microenvironment has also been 
appreciated to mediate therapeutic resistance in pancreatic ductal adenocarcinoma, thus open-
ing numerous avenues for novel therapeutic explorations. Inert and soluble components of the 
tumor stroma have been targeted in order to break down the extracellular matrix scaffold, relieve 
vessel compression, and increase drug delivery to hypovascular tumors. Moreover, targeting of 
antiapoptotic, immunosuppressive, and pro-proliferative effects of the tumor stroma provides 
novel vantage points of attack. This review focuses on current and future developments in pan-
creatic cancer medicine, with a particular emphasis on biophysical and biochemical approaches 
that target the tumor microenvironment.
Keywords: pancreatic cancer, chemoresistance, tumor stroma, drug delivery
Introduction to pancreatic cancer
Pancreatic ductal adenocarcinoma (PDA) is an extremely stroma-rich and highly 
aggressive solid tumor within the exocrine compartment of the pancreatic gland, and 
its incidence rates are steadily increasing in the Western world.1 In the US, an estimated 
43,920 new cases are diagnosed each year, and many diagnosed patients succumb 
to the disease after only a few months.2 The inability of clinicians to substantially 
improve the prognosis of PDA patients over the last few decades is reflected in a 
virtually unchanged 5-year survival rate of 5%–6% and a median survival of less than 
12 months.2 Potential reasons for such a poor clinical outcome reflect both the clinical 
and biological characteristics of pancreatic cancer. First, PDA is chiefly a disease of 
the elderly, and patients often initially note relatively nonspecific symptoms, includ-
ing back pain and dyspepsia.3 These symptoms often point towards degenerative and 
relatively harmless conditions that may not immediately raise concerns on the part 
of patients and general practitioners. More alarming symptoms include new onset of 
diabetes,4–6 painless jaundice, weight loss, or spontaneous deep vein thrombosis.7,8 As 
a result, a timely diagnostic work-up, including use of specialized imaging modali-
ties such as abdominal ultrasound scans, computed tomography (CT), or magnetic 
resonance imaging is often delayed for several months after initial symptom onset.9 
Second, no specific blood or urine biomarkers are presently available that would help 
to identify subgroups of patients with increased risk of developing PDA. Due to these 
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issues and the lack of early detection methods, 80% of PDA 
patients are diagnosed with unresectable locally advanced 
or metastatic disease.
Families having at least two first-degree relatives with 
confirmed PDA that does not meet the criteria of other 
inherited tumor syndromes, such as Peutz–Jeghers syndrome 
or hereditary chronic pancreatitis, comprise a small subset 
of the overall population of PDA patients (5%–10%).10 
Increased surveillance by high resolution imaging and various 
chemopreventive strategies are under investigation as poten-
tial modalities to detect PDA early or prevent its onset.11–16 
While the optimal treatment of locally advanced PDA with-
out detectable distant metastases remains to be determined, 
patients with distant metastases are candidates for systemic 
palliative chemotherapy dependent on comorbidities and 
general performance status. A relative minority of patients 
(15%–20%) who qualify for pancreatic resection receive a 
6-month course of adjuvant gemcitabine or 5-fluorouracil 
plus folinic acid chemotherapy (Figure 1).17 Perioperative 
morbidity and mortality have improved in high-volume 
centers owing to improved surgical resection techniques, 
postoperative care, and multidisciplinary approaches;18–20 
however, tumor relapse is unfortunately common, and the 
median survival rate for patients with R0 resection is approxi-
mately 2 years, with a 5-year survival of 15%–20%.21
This review focuses on current and future developments 
in pancreatic cancer medicine, with a particular emphasis on 
novel treatment options that target the tumor microenviron-
ment, in particular the tumor stroma.
Patient outcomes and current 
treatment options
Despite intensive clinical research activities aiming to iden-
tify effective chemotherapies, PDA has remained virtually 
unresponsive to conventional and targeted therapies.22 A large 
number of randomized clinical trials have been conducted 
in an attempt to improve overall survival in PDA patients. 
To this end, the nucleoside analogue gemcitabine was 
combined with a second cytotoxic agent, eg, 5-fluorouracil, 
capecitabine, cisplatin, oxaliplatin, irinotecan, pemetrexed, 
or exatecan, but all combinations failed to achieve significant 
improvement in overall survival.23–29 Although much hope lay 
in novel targeted therapies such as the vascular endothelial 
growth factor inhibitor bevacizumab,30 the matrix metal-
loproteinase inhibitor marimastat,31,32 and the antiepidermal 
growth factor receptor agent cetuximab,33,34 none of these 
drugs alone or in combination with standard chemotherapies 
had a significant impact on patient outcome. Therefore, the 
relatively well tolerated nucleoside analogue gemcitabine 
remained the standard of care chemotherapy in most coun-
tries, mainly on the basis of modest patient benefit with only 
a marginal increase in median survival.35
The only targeted agent that has been approved for PDA 
patients is the epidermal growth factor receptor tyrosine 
kinase inhibitor erlotinib (Tarceva®, Genentech, CA, USA), 
since the combination of gemcitabine and erlotinib con-
ferred a marginal survival benefit over gemcitabine alone 
(6.24 months versus 5.91 months).36 Although statistically 
significant, the clinical relevance remains questionable. 
More recently, the  gemcitabine-free FOLFIRINOX protocol 
(folinic acid, fluorouracil, irinotecan, and oxaliplatin) was 
reported, and achieved a significant survival benefit for 
patients with metastatic PDA compared with gemcitabine 
monotherapy (11.1 months versus 6.8 months).37 Although 
FOLFIRINOX significantly improves quality of life com-
pared with gemcitabine,38 severe side effects such as grade 
3 and 4 neutropenia and dehydration limit the use of this 
aggressive combination chemotherapy to carefully selected 
patients with good performance status. More recently, results 
from the Phase III Metastatic Pancreatic Adenocarcinoma 
Trial (MPACT) in 861 patients comparing nanoformulated 
albumin-bound paclitaxel (nab-paclitaxel, Celgene, NY, 
USA) with gemcitabine and gemcitabine monotherapy were 
presented. The data show a significant survival benefit for the 
combination of nab-paclitaxel and gemcitabine (8.5 versus 
6.7 months), with a reasonable toxicity profile.39 Although 
the mechanism of action of nab-paclitaxel remains unclear, 
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Figure 1 Schematic overview of current clinical treatment strategies for pancreatic 
cancer patients according to whether they have resectable, locally advanced, or 
metastatic pancreatic cancer, and eCOG performance status 0–5.
Notes: eCOG 0, fully active without restrictions; eCOG 1, restricted in hard 
physical work, but ambulatory and able to carry out light work. The FOLFiRiNOX 
protocol includes folinic acid, fluorouracil, irinotecan, and oxaliplatin.
Abbreviations: 5-FU, 5-fluorouracil; ECOG, Eastern Cooperation Oncology Group; 
PDA, pancreatic ductal adenocarcinoma; nab-paclitaxel, albumin-bound paclitaxel.
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its tolerability profile is superior to that of conventional 
paclitaxel  dissolved in cremophor, and the MPACT regi-
men will likely become a new standard of care treatment 
and new backbone for novel targeted therapies in the future. 
Furthermore, the nab-paclitaxel and gemcitabine combi-
nation is undergoing investigation in localized resectable 
and unresectable PDA for its potential clinical benefit in 
these disease stages. Figure 1 shows the different clinical 
treatment algorithms for resectable, locally advanced, and 
metastasized PDA.
Cellular and molecular evolution  
of pancreatic cancer
Pancreatic carcinogenesis occurs through an accumulation of 
genetic alterations that result in deregulation of tumor cell-
autonomous and nontumor cell-autonomous pathways. These 
genetic changes are accompanied by typical morphologic and 
histologic alterations in epithelial, stromal, and inflammatory 
cells within the pancreas that eventually culminate in desmo-
plastic, highly invasive, and metastatic ductal adenocarcinoma. 
Activating mutations in the K-ras gene represent a signature 
event in almost all pancreatic cancers (.90%), followed by 
subsequent somatic mutations involving the tumor suppres-
sor genes p16, p53, and DPC4/SMAD4.40–45 Interestingly, the 
number of actual mutations of these key drivers of pancreatic 
carcinogenesis correlates positively with a poor prognosis and 
shortened survival for patients.46 Mechanistically, oncogenic 
K-ras activation governs a multitude of mitogenic signals 
with profound cell-autonomous and noncell-autonomous 
effects that initiate epithelial transformation, dynamic rear-
rangement of a proinflammatory and immunosuppressive 
microenvironment, metabolic requirements, and finally drive 
frank malignancy.47–54 Recent evidence from genetically engi-
neered mouse models (GEMMs) with pancreas-specific and 
doxycycline-inducible expression of oncogenic K-rasG12D indi-
cates that abrogation of mutant K-ras in established tumors led 
to dramatic tumor shrinkage and depletion of the surrounding 
stroma after only a few days,55,56 further highlighting the key 
function of mutant K-ras in shaping tumor biology in PDA.
Global sequencing analysis and transposon-mediated 
insertional mutagenesis screens have also discovered genetic 
alterations at low frequency and provide multiple examples 
for the genomic instability and heterogeneity of PDA.57–59 
For the small subset of patients with inherited predisposi-
tion to PDA, several germline mutations, including BRCA2, 
STK11/LKB1, p16/CDKN2A, ATM,60 and PRSS1, have been 
reported.10
Alongside these molecular discoveries, a unique histo-
pathologic progression model similar to that of the adenoma-
carcinoma sequence in the development of colon cancer61 was 
proposed to describe the progression from a normal pancreas 
via preneoplastic lesions to invasive cancer.62,63 Preneoplastic 
lesions are classified as pancreatic intraepithelial neoplasms 
(PanINs) 1a/b, 2, and 3, according to their stepwise accu-
mulation of histopathologic and molecular alterations. The 
discovery that high-grade PanIN lesions increase the risk 
of developing PDA has sparked attempts to detect these 
lesions early by cross-sectional and endoscopic imaging 
techniques.16,64,65 Further, early (partial) pancreatectomy in 
patients with high-grade PanIN lesions is considered in high-
risk individuals (eg, familial PDA), but the ideal timing is 
still debated and data on overall survival from randomized 
clinical trials are currently not available.10
The traditional PanIN-PDA sequence (“ductal 
carcinogenesis”) has recently been challenged by the descrip-
tion of an alternative route of pancreatic carcinogenesis known 
as “acinoductal carcinogenesis”. Careful histopathologic 
investigations by Esposito et al identified tubular complexes 
within areas of acinar ductal metaplasia that form atypical 
flat lesions and may bypass the common PanIN precursor 
stages and directly evolve to invasive cancer.66–68 Histologic 
analysis of sporadic PDA cases confirmed the presence of 
tubular complexes in almost 80% of cases, and atypical flat 
lesions were also detected in cases of familial pancreatic 
cancer. These exciting findings need to be confirmed in larger 
series of sporadic pancreatic cancer cases and may provide 
novel insights into the development of PDA, with potentially 
profound implications in future diagnostic and preventive 
algorithms. Interestingly, earlier studies in GEMMs of pan-
creas cancer had also pointed towards a putative role of the 
acinar cell compartment in driving carcinogenesis with and 
without concomitant inflammation.69–72
Role of the stroma  
in pancreatic cancer
Histologically, PDA is an extremely stroma-rich and hypo-
vascular tumor, and indeed, most of the pancreatic tumor 
mass consists of activated (myo)fibroblasts, immune cells, 
and extracellular matrix components, such as collagen, 
desmin, fibronectin, and hyaluronic acid.9,73,74 Over recent 
years, it has become increasingly evident that the complex 
network of soluble cytokines, growth factors, proteases, and 
extracellular matrix components collaboratively interact 
within the tumor microenvironment, sustaining and driving 
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cancer cell proliferation, invasion, early metastasis, and 
therapeutic resistance.75–80 An important subtype within the 
stromal population is pancreatic stellate cells, which have 
emerged as pancreas-specific myofibroblasts and share mor-
phologic and functional characteristics with hepatic stellate 
cells.81–83 Activated pancreatic stellate cells secrete profibrotic 
proteins abundantly and interact with tumor cells in multiple 
ways to establish and maintain the pronounced desmoplastic 
reaction in PDA (Figure 2).84–86 The clinical relevance is 
highlighted by histologic characteristics of patient samples, 
suggesting that the extent of the stromal reaction correlates 
with shortened survival in patients undergoing surgery.87 The 
complex cellular and biochemical interactions of pancreatic 
stellate cells and cancer cells have limited faithful in vitro 
investigation to traditional two-dimensional coculture assays 
in the laboratory. Therefore, intensive efforts are currently 
being made to establish three-dimensional or organotypic 
culture systems where cancer cells and stromal cells can be 
grown within a reconstituted extracellular matrix gel to study 
the tumor-stromal crosstalk and test novel compounds.88,89
The advent of various GEMMs of pancreas cancer has 
marked a milestone for the scientific community in understand-
ing the biological implications of the tumor stroma and provides 
ample opportunities for preclinical testing of novel agents 
directed against cell-autonomous and noncell-autonomous 
targets.90–93 The most commonly used pancreatic cancer GEMM 
bears an activating K-rasG12D allele that is conditionally activated 
in pancreatic progenitor cells by crossing mice with transgenic 
strains that express Cre recombinase in pancreatic lineages 
(PdxCre or p48Cre). These mice are referred to as “KC” mice 
and develop murine PanIN lesions with 100% penetrance, 
and progress to PDA with a long latency.94 The addition of a 
dominant negative mutation in the tumor suppressor gene p53 
(Trp53R172H/+) greatly accelerates pancreatic tumor development 
and penetrance at an early age, and these mice are accordingly 
termed “KPC” mice.95 In contrast with traditional xenograft 
tumors, GEMMs faithfully recapitulate human PDA, including 
the presence of abundant tumor stroma and comorbidities such 
as cachexia, jaundice, metastasis to distant sites, and activation 
of biochemical pathways. Although the KPC is a faithful mouse 
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Figure 2 Schematic of tumor microenvironment crosstalk and interdependence in PDA, with a particular focus on novel experimental therapeutic interventions and clinical trials. 
Notes: Left bottom panel: PSC and CAF exert immunosuppressive, growth-promoting, and antiapoptotic effects on tumor cells, and can be targeted by inhibition of SHH 
and CTGF. Upper left panel: eCM components providing a scaffold for tumor cells, creating barriers for drug delivery, and providing a variety of prosurvival signals for tumor 
cells. Upper right panel: Tumor vessels are compressed by dense tumor stroma, and vessel density is low due to antiangiogenic factors in the eCM scaffold. The hypoxic 
environment causes an aggressive tumor phenotype, and tumor vasculature can be targeted by SHH and gamma secretase inhibitors. Lower right panel: immune cells create 
an immunosuppressive microenvironment allowing pancreatic tumors to progress, and immunotherapeutic approaches such as agonist CD40 antibodies or anti-GM-CSF 
antibodies reverse this phenotype. Novel agents/regimens directly targeting tumor cells are nab-paclitaxel + gemcitabine and FOLFiRiNOX. Selected ongoing and recently 
completed clinical trials are mentioned by National Clinical Trial (NCT) number, and details can be obtained online at http://clinicaltrials.gov/. The FOLFiRiNOX protocol 
includes folinic acid, fluorouracil, irinotecan, and oxaliplatin.
Abbreviations: Ab, antibody; CAF, cancer-associated fibroblasts; CTGF, connective tissue growth factor; ECM, extracellular matrix; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; PDA, pancreatic ductal adenocarcinoma; PSC, pancreatic stellate cells; SHH, Sonic Hedgehog; nab-paclitaxel, albumin-bound paclitaxel.
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model of PDA, the resources and staffing required to maintain, 
image, and treat a large cohort of animals is substantial and 
beyond the practical abilities of a single laboratory.
The first ultrasound-guided and controlled preclini-
cal study in KPC mice was performed by Ken Olive in 
the Tuveson laboratory and targeted the profibrotic Sonic 
Hedgehog (SHH) pathway. SHH plays important roles dur-
ing pancreas organ development, and is re-expressed during 
malignant transformation to activate and expand stromal 
rather than epithelial cells, thus promoting desmoplasia in 
pancreatic carcinogenesis.96–98 Strikingly, pharmacologic 
inhibition of SHH by the smoothened inhibitor IPI-926 
resulted in marked stromal depletion and increased microves-
sel density and patency, paralleled by significantly improved 
delivery of several chemotherapeutics in the KPC mouse 
model.99 Although the intrinsic effects of SHH inhibition on 
chemosensitivity could not be excluded, this study identified 
the tumor stroma as a biophysical barrier for drug delivery. 
Thus, the tumor microenvironment, in particular the dense 
tumor stroma, is now considered to be a potential reason 
for the failure of most systemic therapies in PDA. Indeed, 
hypoenhancing masses are visualized in PDA patients when-
ever contrast-enhanced imaging is used, and poor perfusion 
has been associated with an aggressive phenotype.100
Novel targets in the  
microenvironment  
of pancreatic cancer
The biophysical role of the pancreatic tumor stroma as a barrier 
to drug delivery has been the focus of intensive clinical and 
preclinical research over the last 3 years, and also attracted 
attention in other tumor entities.101,102 Surprisingly, an SHH 
inhibitor IPI-926 (saridegib, Infinity, MA, USA) and GDC-0449 
(vismodegib, Genentech, CA, USA) both failed in Phase II 
clinical trials, and investigations are still ongoing to compre-
hend the discrepancy between the clinical and preclinical data. 
However, the SHH signaling cascade remains an intriguing and 
widely investigated pathway in PDA, and pharmacologic inhibi-
tion may still be a beneficial therapeutic option in the future, 
depending on the specific compound and cotreatments.103
Other solid and soluble components of the tumor 
microenvironment have been targeted in order to break down 
the extracellular matrix scaffold, relieve vessel compression, 
and increase drug accumulation within the tumor (Figure 2). 
One prominent example is the enzymatic depletion of 
hyaluronic acid, a glycosaminoglycan, by human recombi-
nant PEGylated hyaluronidase (PEGPH20). Pancreatic can-
cers are extremely rich in the megadalton form of hyaluronic 
acid, and the solvation of water by hyaluronic acid is thought 
to be responsible for the high interstitial fluid pressure in 
PDA that results in compression of intratumoral blood ves-
sels.104,105 The Hingorani group has shown that treatment with 
PEGPH20 in murine pancreas tumors results in decreased 
levels of intratumoral fluid pressure in PDA, and this group 
and ours have noted that treatment with PEGPH20 results 
in the re-expansion of blood vessels and improved drug 
delivery, accompanied by slowing of tumor growth and pro-
longed survival in KPC mice.106,107 The results of a Phase I/II 
dose-escalation study (NCT01453153) with PEGPH20 in 
combination with gemcitabine in 28 patients with previously 
untreated stage IV pancreatic cancer were presented at the 
2013 annual scientific meeting of the  American Society 
of Clinical Oncology, and suggested promising efficacy, 
particularly in patients with a high intratumoral content of 
hyaluronic acid.108
Connective tissue growth factor (CTGF/CCN2) is a 
pleiotropic growth factor that is overexpressed in human and 
murine pancreas tumors. Therapeutic inhibition of CTGF 
using a monoclonal human antibody (FG-3019, Fibrogen, 
CA, USA) resulted in significantly increased induction of 
tumor cell apoptosis in KPC mice when combined with gem-
citabine.78 Notably, neither stromal depletion nor increased 
drug delivery was observed. Rather, stromal-derived CTGF 
impinged on the antiapoptotic machinery in tumor cells, 
and the X-linked inhibitor of apoptosis protein was down-
regulated upon treatment with FG-3019. Finally, cotreatment 
with FG-3019 and gemcitabine resulted in slowing of murine 
tumors and prolonged survival in KPC mice.78 FG-3019 in 
combination with gemcitabine and erlotinib (an epidermal 
growth factor receptor tyrosine kinase inhibitor) is currently 
being investigated in a Phase I safety and bioactivity study 
in patients with locally advanced and metastasized PDA 
(NCT01181245).
Secreted protein acidic and rich in cysteine (SPARC) is 
overexpressed by cancer-associated fibroblasts and represents 
another intriguing target in PDA. Results from a Phase I/II 
clinical study showed that patients with high stromal SPARC 
levels responded better to nab-paclitaxel and gemcitabine 
(median survival 17.8 months versus 8.1 months for low 
SPARC),109 suggesting that the albumin-binding protein 
SPARC may act as a novel biomarker for PDA that retains 
nab-paclitaxel to accumulate the drug intratumorally. In 
contrast, two independent studies identified high expres-
sion of SPARC as a negative prognostic marker for patients 
with resectable and unresectable PDA.110,111 Our group has 
undertaken several preclinical studies regarding SPARC and 
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the efficacy and mechanism of action of nab-paclitaxel in 
 combination with gemcitabine. We reported remarkable 
therapeutic efficacy for nab-paclitaxel in highly treatment-
resistant KPC tumors. Importantly, nab-paclitaxel was much 
better tolerated than cremophor-paclitaxel and could be 
administered in more than four-fold higher concentrations. 
Moreover, we identified a synergistic effect of nab-paclitaxel 
through reactive oxygen species-mediated degradation of 
the primary gemcitabine-metabolizing enzyme, cytidine 
deaminase. Therefore, combinations of nab-paclitaxel and 
gemcitabine resulted in increased intratumoral gemcitabine 
levels.112 However, genetic ablation of SPARC in the KPC 
model neither resulted in decreased intratumoral (nab-)
paclitaxel levels nor altered the response to treatment.113 
Nonetheless, elevated serum SPARC levels may play a role 
in paclitaxel uptake in certain PDA patients and could be 
investigated noninvasively in PDA patients prior to starting 
nab-paclitaxel-based chemotherapies.113 The exact function 
of SPARC and the mechanism of action of nab-paclitaxel 
remains a subject of intense clinical114 and preclinical 
investigation,115 and will help to systematically evaluate the 
predictive power of different in vivo models by rigorous com-
parison with the human data. To this end, tissue analysis of 
the MPACT trial is anxiously awaited by the field and should 
provide more answers on this exciting topic.
Partly owing to the hypovascular state of PDA, hypoxia 
is considered a hallmark feature that may predict more 
aggressive behavior and impair the response to therapies 
by providing a niche for slow-cycling, highly drug-resistant 
cells.116–118
Chemotherapeutic agents such as TH-302 are selectively 
activated in the hypoxic tumor microenvironment and are 
currently being investigated in preclinical119 and several clini-
cal trials in PDA patients (NCT01746979, NCT00743379, 
NCT01144455, NCT01833546). Hypoxia is also known to 
stimulate the Notch signaling pathway, and gamma secretase 
inhibitors are currently under early clinical investigation in 
PDA patients (NCT01232829, NCT01098344).  Experimental 
data in human cell lines and GEMMs underscore the thera-
peutic potential of Notch inhibitors in inducing treatment 
responses.120,121
The field of cancer immunotherapy is rapidly evolving 
and has recently provided fascinating insights into pancre-
atic carcinogenesis with potential therapeutic implications 
for patients. For instance, tumor-derived granulocyte-
macrophage colony-stimulating factor has been ascribed a 
central role in mediating a proinflammatory and immunosup-
pressive tumor microenvironment in PDA, and abrogation 
of granulocyte-macrophage colony-stimulating factor 
blocked tumor development by inhibition of Gr-1+ CD11b+ 
and recruitment of cytotoxic CD8+ T-cells into the tumor 
microenvironment.122,123 However, immune surveillance does 
not inevitably depend on therapy-induced T-cells. A combined 
Phase I preclinical-clinical study (NCT00711191) investi-
gated the effects of a CD40 agonist antibody in 21 patients 
with metastatic PDA, and showed promising clinical activity, 
with tumor regression in some patients.124,125 Mechanistically, 
activated macrophages, but not activated T-cell-infiltrated 
tumors, induced tumor cell death and depleted the tumor 
stroma.124 This is the first clear example that shows how 
closely interconnected the immune cell and stromal cell 
compartment is in PDA, and suggests that critical cross points 
between immune and stromal cells must be interrupted in 
order to achieve robust treatment responses.
Conclusion and future perspectives
Tumor-stromal interactions are highly complex and con-
tribute to the key hallmarks of cancer, such as sustained 
proliferative signaling, angiogenesis, activation of invasion, 
and metastasis, as well as extracellular matrix remodeling.126 
More recently, the tumor microenvironment has been increas-
ingly appreciated as being instrumental in mediating resis-
tance to therapy in PDA and other cancers, thus opening up 
numerous avenues for therapeutic exploration, for both the 
biophysical and biochemical approaches described above.
Emerging evidence of metabolic reprogramming driven 
by oncogenic K-ras,56 and the dependency on autophagy,51 
a catabolic pathway degrading cellular organelles and mac-
romolecules, highlight additional metabolic targets that will 
be investigated in the near future. Further, exciting data have 
been reported recently by the Fearon group in Cambridge, 
UK, showing that a subtype of stromal cells expressing fibro-
blast activation protein-α not only cause failure of immune 
surveillance in murine tumors but may also contribute to 
tumor syndromes, such as cachexia and anemia,127 symptoms 
that are most relevant for patient well-being and survival.
A critical and clinically relevant issue remains the dynam-
ics of tumor cell dissemination, and whether PDA metas-
tasizes early or late during disease progression. Whereas 
deep sequencing data for human PDA suggested a long 
latency (on average 17 years) for the occurrence of distant 
metastases,71 a computational analysis of 228 PDA patients 
supported the notion that spread of malignant cells repre-
sents an early event during carcinogenesis, and most patients 
may harbor distant metastases at earlier disease stages 
than previously anticipated.128 Provocative lineage tracing 
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experiments in GEMMs of pancreatic cancer proposed a 
mechanism by which single mutant cells detach from the 
basement membrane by epithelial-to-mesenchymal transi-
tion to enter the blood circulation prior to the development 
of frank malignancy. The disseminated cells seeded the liver 
and showed stem cell properties, a process that was further 
promoted by pancreatic inflammation.129
These studies must be confirmed independently but may 
transform our understanding of the evolution of pancreatic 
cancer and prioritize our efforts toward investigational 
clinical trials that compare neoadjuvant cytotoxic and anti-
metastatic therapies with upfront surgery. Also, patients at 
risk for developing pancreatic cancer (eg, Peutz–Jeghers syn-
drome, hereditary pancreatitis, familial pancreatic cancer) 
should be considered for evaluation of anti-inflammatory 
and antimetastatic therapeutic approaches. Moreover, these 
studies may open new avenues to understand the genetic, 
epigenetic, and microenvironmental determinants that may 
explain long-term survivors and those who never develop 
metastases.130
GEMMs of PDA that recapitulate important aspects of 
the tumor microenvironment are critical tools for inves-
tigating tumor-stromal interactions in the laboratory and 
for testing novel compounds that target components of the 
microenvironment prior to clinical testing. Given the long 
list of failed clinical trials in the past, it remains speculative 
which compounds will make the difference for patients with 
pancreatic cancer. Therefore, it is timely for the field to con-
sider including these GEMMs prior to evaluating therapies 
in the clinic.
To enhance our molecular understanding of treat-
ment success or failure, clinicians should seek to obtain 
pretreatment biopsies from patients via endoscopic 
ultrasound-guided fine needle aspiration biopsy or endo-
scopic ultrasound-guided core biopsy. Limitations in the 
quantity and quality of biopsy samples requires optimized 
approaches to obtain tissue specimens for histologic and 
immunohistochemical analysis of stromal, inflammatory, 
and parenchymal tissue components,131 and post-treatment 
biopsies are highly desirable for monitoring the effects of 
treatment on tumor biology and to prospectively explore 
potential biomarkers.  Contrast-enhanced endoscopic 
ultrasound combined with elastography is an additional 
noninvasive technique that may provide useful information 
before and during therapies.114,132,133 Further, experimental 
molecular imaging approaches in various mouse models 
of pancreas cancer have recently identified potentially 
promising candidates, such as plectin-1, cathepsins, and 
the tight-junction protein claudin-4, that could be deployed 
for early detection,134–137 and should now be rigorously 
evaluated in the clinical setting to improve early diagnosis 
of PDA.
To conclude, the last few years have seen a virtual explo-
sion of knowledge in the field of basic and translational 
pancreatic cancer research, and we are hopeful that the 
continuing effort to translate these findings to the clinic will 
eventually benefit our patients. Targeting the tumor microen-
vironment provides a novel and much needed vantage point 
of attack, and we anticipate that several of the components 
within the tumor microenvironment described here will 
be exploited to achieve robust treatment responses for this 
recalcitrant tumor.
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